We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.69%
AUM
$1.34B
AUM Growth
-$123M
Cap. Flow
-$153M
Cap. Flow %
-11.43%
Top 10 Hldgs %
26.37%
Holding
215
New
22
Increased
46
Reduced
51
Closed
31

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$30.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$21.3M
3
BWXT icon
BWX Technologies
BWXT
+$17.1M
4
CBAY
Cymabay Therapeutics
CBAY
+$15.2M
5
IMGN
Immunogen Inc
IMGN
+$14M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$37.8M
2
INSP icon
Inspire Medical Systems
INSP
+$37.4M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$35.7M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$19.3M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 52.08%
2 Technology 13.86%
3 Industrials 8.87%
4 Energy 5.36%
5 Financials 5.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$52B
$46M 3.44%
93,566
-1,848
-2% -$904K
KRYS icon
2
Krystal Biotech
KRYS
$9.21B
$41.3M 3.08%
355,611
-19,340
-5% -$2.36M
LEGN icon
3
Legend Biotech
LEGN
$3.68B
$39.8M 2.97%
593,010
-157
-0% -$10.9K
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.38B
$37.9M 2.83%
1,199,366
+284,247
+31% +$7.78M
ROIV icon
5
Roivant Sciences
ROIV
$24.1B
$35M 2.62%
2,998,135
+732,812
+32% +$8.28M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$119B
$33M 2.46%
94,758
+14,642
+18% +$5.12M
IMGN
7
DELISTED
Immunogen Inc
IMGN
$32.8M 2.45%
2,067,561
+843,434
+69% +$14M
ESTA icon
8
Establishment Labs
ESTA
$2.73B
$30.5M 2.27%
620,622
+84,607
+16% +$5.06M
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.02B
$29.2M 2.18%
854,447
+63,329
+8% +$2.37M
CYTK icon
10
Cytokinetics
CYTK
$10.4B
$27.8M 2.07%
942,137
+259,270
+38% +$8.63M
AXSM icon
11
Axsome Therapeutics
AXSM
$10.9B
$27.6M 2.06%
394,980
+96
+0% +$7.18K
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$27.4M 2.05%
1,840,014
+1,143,067
+164% +$15.2M
DAWN
13
DELISTED
Day One Biopharmaceuticals
DAWN
$26.9M 2.01%
2,188,654
-48,457
-2% -$632K
IMCR icon
14
Immunocore
IMCR
$1.65B
$26.6M 1.99%
512,855
+508,155
+10,812% +$30.1M
MRK icon
15
Merck
MRK
$316B
$25.2M 1.88%
244,934
– –
PCVX icon
16
Vaxcyte
PCVX
$7.73B
$23.5M 1.75%
460,008
-156
-0% -$7.7K
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.68B
$22.8M 1.7%
+188,085
New +$21.3M
TMDX icon
18
Transmedics
TMDX
$2.82B
$22.7M 1.69%
413,714
+46,083
+13% +$3.32M
VRNA
19
DELISTED
Verona Pharma
VRNA
$19M 1.42%
1,162,989
-366
-0% -$7.05K
CELH icon
20
Celsius Holdings
CELH
$7.22B
$17.9M 1.33%
312,282
-19,656
-6% -$1.11M
BWXT icon
21
BWX Technologies
BWXT
$15.9B
$17.8M 1.33%
+237,063
New +$17.1M
LNTH icon
22
Lantheus
LNTH
$6.59B
$17.7M 1.32%
254,752
-15,017
-6% -$1.1M
XOM icon
23
ExxonMobil
XOM
$643B
$17.7M 1.32%
150,500
-12,500
-8% -$1.37M
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.5M 1.31%
335,554
-163,949
-33% -$9.55M
LSCC icon
25
Lattice Semiconductor
LSCC
$18B
$16.6M 1.24%
192,686
-662
-0.3% -$59.8K
1
2 3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Nicholas Investment Partners held 215 positions worth $1.34B, down 8.4% from $1.46B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Nicholas Investment Partners withdrew a net $153M in Q3 2023, closing 31 positions and reducing 51 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $37.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 54% a quarter earlier, followed by Technology and Industrials.

Against the trend, Nicholas Investment Partners opened a new position in Sarepta Therapeutics worth $22.8M.

  • Nicholas Investment Partners's largest Q3 2023 buy was Sarepta Therapeutics: 188,085 shares worth $22.8M.
  • Nicholas Investment Partners added most to Immunocore in Q3 2023, an estimated $30.1M increase.
  • Nicholas Investment Partners's biggest Q3 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $12M.
  • Nicholas Investment Partners fully exited Apellis Pharmaceuticals in Q3 2023, selling an estimated $37.8M.
  • Nicholas Investment Partners's ten largest holdings make up 26% of its $1.34B portfolio in Q3 2023.
  • Nicholas Investment Partners opened 22 new positions and closed 31 in Q3 2023.
  • Nicholas Investment Partners's portfolio value fell 8.4% quarter-over-quarter to $1.34B.

Based on Nicholas Investment Partners's 13F filing for Q3 2023, filed 13 Nov 2023.